Form 4: Revolution Medicines' General Counsel, Jeff Cislini, Executes Stock Sale Under 10b5-1 Plan

Jeff Cislini, General Counsel of Revolution Medicines, sold 2,399 shares of common stock at $40.83 per share on July 9, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On July 9, 2024, Jeff Cislini, the General Counsel of Revolution Medicines, sold 2,399 shares of common stock.
• The sale was executed at a price of $40.83 per share.
• This transaction was conducted under a pre-existing 10b5-1 trading plan adopted on March 20, 2024.
• Following the transaction, Cislini directly owns 47,088 shares, which includes 44,217 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged trading plan, which doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when corporate insiders, like officers and directors, trade their company's stock. These filings are closely watched by investors for insights into management's perspective on the company's value and future prospects. The use of a 10b5-1 trading plan suggests the insider is selling shares in a pre-planned manner to avoid accusations of trading on non-public information.

Comparison to Industry Standards

• Comparing this transaction to similar Form 4 filings of other biotech companies, the sale of 2,399 shares is relatively small.
• For example, executives at companies like Amgen or Gilead Sciences often trade significantly larger volumes of shares.
• The use of a 10b5-1 plan is a common practice among executives to diversify their holdings and manage personal finances while avoiding potential insider trading concerns, aligning with industry best practices.

Stakeholder Impact

• The sale of shares by a company insider could be perceived negatively by some shareholders, potentially creating short-term selling pressure.
• However, the existence of a 10b5-1 trading plan mitigates concerns about insider trading, reassuring stakeholders that the sale was pre-planned and not based on any non-public information.

Key Dates